Precision | Jotup

Precision Drilling Completes Acquisition of CWC Energy Services Corp.

Retrieved on:

Mercredi, novembre 8, 2023

Precision Drilling, PDS, CWC, News, Disclosure, PD, Precision, NYSE, TSX, Acquisition

Precision Drilling Corporation (“Precision” or the “Company”) (TSX:PD; NYSE:PDS) is pleased to announce that it has completed its acquisition of CWC Energy Services Corp. (“CWC”).

Key Points:

Precision Drilling Corporation (“Precision” or the “Company”) (TSX:PD; NYSE:PDS) is pleased to announce that it has completed its acquisition of CWC Energy Services Corp. (“CWC”).
The total consideration for CWC included 947,807 Precision common shares, approximately $14 million in cash, plus the assumption of CWC’s net debt of approximately $38 million, excluding transaction costs.
The total transaction value for CWC was approximately $127 million on November 7, 2023.
I am excited to welcome the CWC employees to the Precision team.”
Precision has acquired all of the issued and outstanding shares of CWC, with each CWC shareholder receiving, at their election (a) 0.002124306 of a Precision share for each CWC share; (b) $0.196668 in cash for each CWC share; or (c) a combination of cash and Precision shares, subject to proration.

Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep

Retrieved on:

Jeudi, novembre 9, 2023

Therapy, Precision, US, Pancreatic Cancer Action Network, Data, FOLFIRINOX, AB, Pancreatic cancer, Hand, Cancer, ONC, Patient, TSX, SAN, Pharmaceutical industry, Oncolytics Biotech, Pelareorep, PDAC

SAN DIEGO, CA and CALGARY, AB, Nov. 9, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (Oncolytics) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, provided an update on the planned program for pelareorep in pancreatic ductal adenocarcinoma (PDAC).

Key Points:

SAN DIEGO, CA and CALGARY, AB, Nov. 9, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (Oncolytics) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, provided an update on the planned program for pelareorep in pancreatic ductal adenocarcinoma (PDAC).
Oncolytics' collaborator, The Pancreatic Cancer Action Network (PanCAN), a pancreatic cancer patient advocacy organization, advised the company that it is implementing a strategic re-evaluation of the Precision PromiseSM program and will not be adding any new investigational therapies to the platform until the re-evaluation is complete.
Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics, said, "Oncolytics remains steadfast in its commitment to initiate the Phase 3 program for pelareorep, starting in PDAC, in 2024.
Having a compelling Phase 2 dataset in hand and strong connections with the pancreatic cancer community, Oncolytics is well positioned to effectively conduct the Phase 3 pancreatic cancer program.

Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep

Retrieved on:

Jeudi, novembre 9, 2023

Therapy, Precision, US, Pancreatic Cancer Action Network, Data, FOLFIRINOX, AB, Pancreatic cancer, Hand, Cancer, ONC, Patient, TSX, SAN, Pharmaceutical industry, Oncolytics Biotech, Pelareorep, PDAC

SAN DIEGO, CA and CALGARY, AB, Nov. 9, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (Oncolytics) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, provided an update on the planned program for pelareorep in pancreatic ductal adenocarcinoma (PDAC).

Key Points:

SAN DIEGO, CA and CALGARY, AB, Nov. 9, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (Oncolytics) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, provided an update on the planned program for pelareorep in pancreatic ductal adenocarcinoma (PDAC).
Oncolytics' collaborator, The Pancreatic Cancer Action Network (PanCAN), a pancreatic cancer patient advocacy organization, advised the company that it is implementing a strategic re-evaluation of the Precision PromiseSM program and will not be adding any new investigational therapies to the platform until the re-evaluation is complete.
Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics, said, "Oncolytics remains steadfast in its commitment to initiate the Phase 3 program for pelareorep, starting in PDAC, in 2024.
Having a compelling Phase 2 dataset in hand and strong connections with the pancreatic cancer community, Oncolytics is well positioned to effectively conduct the Phase 3 pancreatic cancer program.

Guidehouse Insights Estimates Global Market for Precision and Autonomous Agriculture Equipment Will Grow to Nearly $29 Billion by 2032

Retrieved on:

Mardi, octobre 31, 2023

Pesticide, Farmer, Agriculture, Research, Fertilizer, PAA, Soybean, Precision, GPS, Herbicide, Software

BOULDER, Colo., Oct. 31, 2023 /PRNewswire/ -- A new report from Guidehouse Insights explores the precision and autonomous agriculture (PAA) market and focuses on drivers and barriers for all PAA technologies on all types of fields.

Key Points:

Precision agriculture uses advanced technology, such as sensors, software, and equipment, to grow crops optimally.
According to a new report from Guidehouse Insights, the global market for all PAA equipment is expected to be worth nearly $28.5 billion by 2032, growing from nearly $4.0 billion in 2023, at a compound annual growth rate (CAGR) of 24.7%.
"The market potential for these technologies is significant," says Jake Foose, research analyst with Guidehouse Insights.
The report, Precision and Autonomous Commercial Agriculture , analyzes the global market for precision and autonomous agriculture.

Precision BioSciences Presents Preclinical Data Highlighting Capabilities of ARCUS for Gene Insertion and Excision at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

Retrieved on:

Jeudi, octobre 26, 2023

“We believe ARCUS has the potential to redefine gene editing by enabling sophisticated gene edits such as gene insertion, excision, and elimination,” said Jeff Smith, Chief Research Officer of Precision BioSciences.

Key Points:

“We believe ARCUS has the potential to redefine gene editing by enabling sophisticated gene edits such as gene insertion, excision, and elimination,” said Jeff Smith, Chief Research Officer of Precision BioSciences.
“ARCUS’ ability to create 4 base pair, 3’ overhangs is designed to make predictable, highly consistent, therapeutic edits and enable high efficiency gene insertion through homology directed repair (HDR).
In preclinical work presented today at ESGCT, ARCUS demonstrated 17 times higher gene insertion efficiency compared to CRISPR-Cas9, validating the importance of the cut made by ARCUS.
ARCUS showed up to ~45% insertion when administered by LNP along with an AAV carrying a gene insertion template in adult NHPs, and demonstrated high efficiency gene insertion via HDR in nondividing, primary human hepatocytes.

Anlev Achieves New Milestones for Global Expansion

Retrieved on:

Mercredi, octobre 18, 2023

United Kingdom, Precision, Acquisition, Trust, City, E&M, TEI, Pico Far East Holdings Limited, JCW, Warehouse, Analog, Limited

When Anlev was founded in 1991, it was envisaged "A New Lift and Escalator Vision" and therefore named Anlev.

Key Points:

When Anlev was founded in 1991, it was envisaged "A New Lift and Escalator Vision" and therefore named Anlev.
Over the years, Anlev has been expanding its business with the mission to provide safe, comfortable, energy efficient and reliable lifts and escalators to global market.
To further its global expansion strategy, Anlev has recently completed two acquisitions in the UK market.
"Anlev will continue to explore suitable synergistic business partnerships that align with our strategic goals and values, and seek new distributors to further our global expansion plan," Dr Poon concluded.

Anlev Achieves New Milestones for Global Expansion

Retrieved on:

Jeudi, octobre 26, 2023

United Kingdom, Precision, Acquisition, Trust, City, JCW, Outreach, Intermodal freight transport, Limited

When Anlev was founded in 1991, it was envisaged “A New Lift and Escalator Vision” and therefore named Anlev.

Key Points:

When Anlev was founded in 1991, it was envisaged “A New Lift and Escalator Vision” and therefore named Anlev.
Over the years, Anlev has been expanding its business with the mission to provide safe, comfortable, energy efficient and reliable lifts and escalators to global market.
To further its global expansion strategy, Anlev has recently completed two acquisitions in the UK market.
“Anlev will continue to explore suitable synergistic business partnerships that align with our strategic goals and values, and seek new distributors to further our global expansion plan,” Dr Poon concluded.

INTRODUCING LIFELINES: INNOVATORS OF SENSORY IMMERSION™

Retrieved on:

Mercredi, octobre 25, 2023

Well, Maker, Flower, Precision, System, Bird, Target, Toy, Melissa, Creativity, Nature, Paraben, Imagination, Category, Hand, Brain, Depression, Smell, Anxiety, Collection, Sensory, Perfume, Lifeline

NEW YORK, Oct. 25, 2023 /PRNewswire/ -- Are you among the 83% of American adults who feel stressed?1

Key Points:

Sensory Immersion is all about seeing, smelling, and touching delightful things to signal to your brain that it's safe to feel good.
Lifelines will offer a comprehensive suite of Sensory Immersion tools across all six senses.
The collection includes 45 products with 16 patents pending, spanning portable fidget tools, sensory writing, innovative diffusers, and essential oil blends.
Tactile Sensory Journals feature covers made for touch, with soothing embossed patterns inside to keep your ideas flowing.

Stephanie Cutter Joins Equality Health Board of Directors

Retrieved on:

Jeudi, octobre 19, 2023

PHOENIX, Oct. 19, 2023 /PRNewswire/ -- Equality Health, a leader in value-based care, today announced the appointment of Stephanie Cutter to its board of directors. Cutter is a highly respected communications and campaign strategist with a successful track record of creating and executing national campaigns to enhance brands and reputations, manage crises, and shape critical public policy issues. She has worked with top political figures and Fortune 500 corporations, and played key roles in high-profile national events.

Key Points:

PHOENIX, Oct. 19, 2023 /PRNewswire/ -- Equality Health, a leader in value-based care, today announced the appointment of Stephanie Cutter to its board of directors.
"I've spent my career working to improve access to quality health care for all Americans," said Stephanie Cutter.
"Equality Health's innovative approach to working with Medicaid providers to deliver better health outcomes and lower costs has the ability to transform our health care system and improve the health of millions of Americans.
A resident of Washington, D.C., Cutter is a graduate of Smith College and Georgetown University Law Center.

Meet Dell's newest workstation - featuring 96 cores

Retrieved on:

Jeudi, octobre 19, 2023

ROUND ROCK, Texas, Oct. 19, 2023 /PRNewswire/ -- Here at Dell Technologies, we are big believers that the workstation industry has always been fast-paced and exciting. We've had a front row seat for more than 25 years helping creators, engineers, architects, researchers and more bring their ideas to life and make an impact on the world. Workstations have played a critical role here, viewed as a necessary tool to make the impossible possible. Now the world is buzzing with AI and generative AI (GenAI), and workstations are in the spotlight in a different way.

Key Points:

That's why we're especially excited to introduce the new Precision 7875 Tower featuring AMD Ryzen™ Threadripper™ PRO 7000 WX-Series processors.
It's Dell's most scalable and powerful AMD processor-based workstation ever.4
Designed for engineers, architects, creatives and product designers, the Precision 7875 Tower is a multithreaded computing workstation for demanding professional applications.
With up to 96 cores, the Precision 7875 Tower has the most cores of any single socket Dell Precision workstation.5
The Precision 7875 Tower is a performance powerhouse.
The workstation can support a variety of AI functions, such as model training, GenAI, machine learning and more.